Home

The Korea Herald

Latest news

Most Popular

  1. 1

    Contentious grain bill put directly to plenary meeting for vote

    Contentious grain bill put directly to plenary meeting for vote
  2. 2

    Yoon's approval rating plunges to all-time low

    Yoon's approval rating plunges to all-time low
  3. 3

    Will tug-of-war between doctors, government end soon?

    Will tug-of-war between doctors, government end soon?
  4. 4

    Climate impacts set to cut 2050 global GDP by nearly a fifth

    Climate impacts set to cut 2050 global GDP by nearly a fifth
  5. 5

    Trilateral talks acknowledge ‘serious’ slumps of won, yen

    Trilateral talks acknowledge ‘serious’ slumps of won, yen
  1. 6

    [Graphic News] More Koreans say they plan long-distance trips this year

    [Graphic News] More Koreans say they plan long-distance trips this year
  2. 7

    [KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs

    [KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs
  3. 8

    North Korea removes streetlights along cross-border roads with South

    North Korea removes streetlights along cross-border roads with South
  4. 9

    Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official

    Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official
  5. 10

    Farming households dip below 1m for first time in 2023

    Farming households dip below 1m for first time in 2023
소아쌤

CJ Healthcare’s K-CAB Tab makes inroads into Thailand

By Lim Jeong-yeo

Published : Nov. 21, 2019 - 16:20

    • Link copied

CJ Healthcare said Thursday it will export its original gastroesophageal reflux disease drug to Thailand’s Pond’s Chemical.

K-CAB Tab (tegoprazan) is listed as the 30th new drug developed by a Korean company. It acquired commercial approval from South Korea’s Ministry of Food and Drug Safety in 2018 and was launched here in March 2019.

Since then, the drug has raked in 18.7 billion won ($15.8 million) in sales.


K-CAB Tab (CJ Healthcare) K-CAB Tab (CJ Healthcare)


K-CAB Tab is already being exported to 17 countries including China, Vietnam, Indonesia and Central American nations.

The market for gastroesophageal reflux disease treatment in Thailand, in the case of the main proton pump inhibitor (PPI) stream, is estimated to be worth around $76 million, according to IQVIA data.

K-CAB is a potassium competitive acid blocker (P-CAB) that offers quick relief of symptoms. Its advantage is that it can be taken any time of the day.

CJ Healthcare expects K-CAB Tab to launch in 2022 after due approval from Thai authorities. It will supply the finished medicine to Pond’s for 10 years.

By Lim Jeong-yeo (kaylalim@heraldcorp.com)

More from Headlines